3203 |
DR-TB Counselling Register |
02/06/2024 |
DR-TB and PMDT |
3243 |
PMDT Review Mechanisms |
02/06/2024 |
DR-TB and PMDT |
3907 |
MTB Drug Resistance |
02/06/2024 |
DR-TB and PMDT |
3908 |
Mechanism of action-anti TB drugs first line and second line |
02/06/2024 |
DR-TB and PMDT |
4329 |
Presumptive NTM |
02/06/2024 |
DR-TB and PMDT |
4331 |
Diagnosis of NTM Lung Disease |
02/06/2024 |
DR-TB and PMDT |
4332 |
Clinical and radiographic manifestations |
02/06/2024 |
DR-TB and PMDT |
4333 |
Laboratory findings of NTM |
02/06/2024 |
DR-TB and PMDT |
4339 |
Radiology in TB Diagnosis |
02/06/2024 |
DR-TB and PMDT |
4341 |
Management of TB Patient - Exteremely Underweight |
02/06/2024 |
DR-TB and PMDT |
4342 |
Management of TB Patient - Severely Underweight |
02/06/2024 |
DR-TB and PMDT |
4343 |
Management of TB Patient - Mild and Moderate Underweight |
02/06/2024 |
DR-TB and PMDT |
4344 |
Management of TB Patient - Normal Weight |
02/06/2024 |
DR-TB and PMDT |
4345 |
Management of TB Patient - Overweight/Obese |
02/06/2024 |
DR-TB and PMDT |
4351 |
Nausea and Vomiting |
02/06/2024 |
DR-TB and PMDT |
4352 |
Diarrhea |
02/06/2024 |
DR-TB and PMDT |
4353 |
Gastritis & pain in abdomen |
02/06/2024 |
DR-TB and PMDT |
4354 |
Yellow discoloration of body parts - Jaundice |
02/06/2024 |
DR-TB and PMDT |
4355 |
Arthralgia - joint pain |
02/06/2024 |
DR-TB and PMDT |
4356 |
Skin rashes, allergic reactions & anaphylaxis |
02/06/2024 |
DR-TB and PMDT |
4357 |
Unsteadiness - Tinnitus and dizziness |
02/06/2024 |
DR-TB and PMDT |
4358 |
Peripheral Neuropathy - Nerve Pain |
02/06/2024 |
DR-TB and PMDT |
4359 |
Tendonitis - Achilles' tendon |
02/06/2024 |
DR-TB and PMDT |
4360 |
Psychiatric behavior |
02/06/2024 |
DR-TB and PMDT |
4579 |
Shorter Injectable-containing MDR/RR-TB Regimen: Eligibility Criteria |
02/06/2024 |
DR-TB and PMDT |
4580 |
Shorter Injectable-containing MDR/RR-TB Regimen: Regimen and Duration |
02/06/2024 |
DR-TB and PMDT |
4797 |
Management of DR-TB ADR: Gastrointestinal Symptoms [Nausea and Vomiting] |
02/06/2024 |
DR-TB and PMDT |
4798 |
ADR: Hearing Loss/ Ototoxicity |
02/06/2024 |
DR-TB and PMDT |
4932 |
EVIDENCE FOR ISONIAZID[H] MONO/POLY DR-TB REGIMEN |
02/06/2024 |
DR-TB and PMDT |
4930 |
Shorter oral Bedaquiline-containing MDR/RR-TB regimen: Evidence |
02/06/2024 |
DR-TB and PMDT |